Stoxline.com
android_stock_chart
Stock Chart

Stoxline Lite

Stoxline Pro

Option Calculator
Stoxline
Mobile

Home | Charts | Showcases | Stock Ranks | Options | ETFs | Educations

 
Tweet this page
Share on Facebook
Share on Google+

7 Binary Options

 

Enter Stock Symbol:  

Syros Pharmaceuticals (SYRS)

11.96 0 (0%)

05-22 16:00

Open:

11.92

Pre. Close:

11.96

High:

12.25

Low:

11.56

Volume:

179,082

Market Cap:

390M

Stock Price Prediction (Update at 5:00pm est.)

If tomorrow:

Open lower

Open higher

High:

12.261 - 12.347

12.347 - 12.414

Low:

11.404 - 11.492

11.492 - 11.561

Close:

11.842 - 11.982

11.982 - 12.09

Technical analysis  (as of: 2018-05-22 4:43:17 PM)

Overall:

      

Stoxline posted a NEUTRAL today, upgraded from lower rating. This stock seems to stay at current move trend, but it could change at anytime. So it is not a good time to buy or sell, stay at where you are until next BUY or SELL signal.

Target:

Six months: 15.06     One year: 16.13

Support:

Support1: 11.40    Support2: 9.49

Resistance:

Resistance1: 12.89    Resistance2: 13.81

Pivot:

12.18

Moving Averages:

MA(5): 12.27     MA(20): 12.18

MA(100): 11.49     MA(250): 14.35

MACD:

MACD(12,26): -0.05     Signal(12,26,9): -0.04

%K %D:

%K(14,3): 47.83     %D(3): 55.15

RSI:

RSI(14): 45.92

52-Week:

High: 24.375  Low: 6.3  Change(%): -30.3

Average Vol(K):

3-Month: 15992  10-Days 17356

Strong Sell ★★ Sell ★★★ Neutral ★★★★ Buy ★★★★★ Strong Buy

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
SYRS has closed above bottom band by 35.5%. Bollinger Bands are 11.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

2018-05-16T17:01:00-04:00
Syros to Present on Design of Ongoing Phase 1 Clinical Trial of SY-1365 at Upcoming ASCO Annual Meeting

2018-05-10T07:37:13-04:00
Syros Pharmaceuticals misses by $0.09, misses on revenue

2018-05-10T07:30:00-04:00
Syros Reports First Quarter 2018 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

2018-05-03T08:01:00-04:00
Syros to Report First Quarter 2018 Financial Results on Thursday, May 10, 2018

2018-04-18T11:49:31-04:00
2 Oversold Small Biotech Stocks

2018-04-16T08:01:00-04:00
Syros Announces New Preclinical Data on SY-1365 Showing Potent Anti-Tumor Activity in Multiple Models of Heavily Pretreated Ovarian Cancer

2018-03-16T10:25:46-04:00
Key events next week - healthcare

2018-03-14T16:30:00-04:00
Syros to Present New Preclinical Data on SY-1365 in Ovarian Cancer at Upcoming AACR Annual Meeting

Financial Analysis

Growth

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.

Profitability

Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.

Solvency

Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.

Efficiency

Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.

Click here to get more fundamental analysis.

 

Free Technical Analysis Charts

Stock Basics & Statistics

Sector:  Healthcare

Industry:  Biopharmaceuticals

Shares Out. (M)

32.48

Shares Float (M)

31.48

% Held by Insiders

3.10

% Held by Institutions

62.40

Shares Short (K)

1360

Shares Short Prior Month (K)

980

Stock Financials

EPS

-2.110

EPS Est. Current Year

-2.090

EPS Est. Next Year

-2.890

EPS Est. Next Quarter

-0.550

Forward EPS

-2.712

Book Value (p.s.)

5.730

PEG Ratio

Profit Margin

Operating Margin

-4966.94

Return on Assets (ttm)

-63.6

Return on Equity (ttm)

-74.0

Qtrly Rev. Growth

-100.0

Gross Profit (p.s.)

Sales Per Share

EBITDA (p.s.)

-0.824

Qtrly Earnings Growth

Operating Cash Flow (M)

-44.73

Levered Free Cash Flow (M)

-25.28

atoplab.com

Valuation

P/E

-5.67

P/E Growth Ratio

P/BV

2.09

P/S

9741419520.00

P/CF

-8.69

Dividend Yield

Dividends & Splits

Dividend

Dividend Pay Date

Invalid DateTime.

Ex-Dividend Date

Invalid DateTime.

Forward Dividend

Last Split Date

Last Split Ratio

-1e+010

 

(c) 2006-2017 Stoxline.com | Contact us | NYSE, NASDAQ, AMEX Stock symbols

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.